معرفی
Albert Powers is an Associate Professor of Psychiatry at Yale University School of Medicine and serves as Medical Director and Associate Director of the Yale PRIME Psychosis Risk Clinic. His work bridges clinical practice and computational neuroscience, focusing on early psychosis intervention and the mechanisms underlying hallucinations.
Dr. Powers' research centers on computational approaches to understanding perceptual dysregulation in psychosis. His work integrates behavioral experiments, computational modeling, and clinical assessment to investigate how sensory systems go awry to produce hallucinations and other psychotic symptoms. He has made significant contributions to understanding prior overweighting in perceptual processing, conditioned hallucinations, and the computational mechanisms of symptom emergence in clinical high-risk populations.
His recent publications reveal a strong focus on collaborative large-scale initiatives like the Accelerating Medicines Partnership® Schizophrenia Program, where he contributes to developing standardized protocols for EEG, MRI, digital health technologies, and clinical assessments across international sites. His work spans theoretical computational psychiatry, clinical translation, and innovative intervention development, including his principal investigator role in the study 'Testing a Computationally-Informed, Personalized Intervention for Hallucinations.'
- Young Physician-Scientist Award (2022) from American Society for Clinical Investigation
- Carol and Eugene Ludwig Award for Early Career Research (2021)
- Second Prize, Yale Digital Pitchfest (2021)
- New Investigator Award (2018) from American Society of Clinical Psychopharmacology
Dr. Powers leads the Powers Lab, which investigates the computational mechanisms of hallucinations and develops novel interventions based on these insights. His research bridges basic science and clinical application, with emphasis on translating computational findings into personalized treatment approaches for individuals experiencing psychosis spectrum symptoms. He maintains active collaborations with researchers across Yale and internationally, particularly within the schizophrenia research community.
